NRTI + PI
Drugtenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
NCT Number: NCT01585753
This is a substudy of MARCH, in which we are exploring the changes in the vascular endothelium using pulse wave tonometry (a non invasive measure of cardiac health) to measure the changes in small and large arterial elasticity in participants of the MARCH study who switch to maraviroc-based regimens over 96 weeks of follow-up.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Fundacion IDEAA, Buenos Aires, Argentina
Cardiovascular disease is increasingly recognised as a complication of HIV +/- therapies to treat it. Blood vessel elasticity, or compliance, can be depicted as the ability of the vessels to convert intermittent blood flow (cardiac ejection during systole) to continuous blood flow throughout the cardiac cycle. The compliance, or ability of vessels to accept energy, can be subdivided into elasticity of large and small vessels. Pulse wave tonometry is a non-invasive technique performed using a hand-held tonometer that generates two indices which correspond to large artery elasticity (LAE) and small artery elasticity (SAE). LAE and SAE estimates by pulse waveform analysis have previously shown greater correlation to Framingham risk when directly compared with other techniques such as flow-mediated diltation, and both LAE and SAE are associated with traditional cardiovascular risk factors (smoking, insulin resistance, hypertension).
It is unclear what the net effect of maraviroc, a chemokine-receptor blocker is on cardiovascular function.
The aims of this substudy are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
Time frame: 96 weeks
measured at 6 timepoints week 0, 4, 12, 24, 48, 96
Time frame: 96 weeks
measured at 6 timepoints, week 0,4,12,24,48,96
Time frame: 96 weeks
stored bloods from the main study will be used to explore changes in vascular biomarkers
Kirby Institute
Other Gov
Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH
Acronym: MARCH VE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738250
Cancer Survivorship, Cardiovascular Disease
View Trial DetailsNCT01778569
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02840448
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial Details